DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
|Articles|March 11, 2022
First Commercial Shipment Using Releye RAP Container
Advertisement
Envirotainer (Stockholm, Sweden) has reported the completion of the first commercial shipment using the new Releye® RAP container.
According to the company, the Releye® RAP “sets a new benchmark for temperature-controlled, five-pallet solutions... Designed to meet the strictest requirements in pharmaceutical air freight, the integrated live monitoring enables a unique insight into product condition, location, and progress of the shipment.”
The shipment started in Basel, Switzerland, landing at JFK airport, New York, and consisted of three Releye RAP units and two RAP e2 units. The shipper was a global acting Swiss pharmaceutical company, and the transportation “went according to plan.”
Integrated live monitoring meant the shipment was checked “in every detail through the whole journey.” Further, the Control Tower service saw a global team of operators ready to respond within minutes to any critical event, should one have occurred.
Advertisement
Related to this article
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.
Simvera PSP applies queueing science so manufacturers can test the cost and patient impact of hub staffing decisions before locking them in.
Gregg Gorniak explains how AI, RFID and serialized data are helping trading partners move DSCSA compliance from a regulatory checkbox to a source of shared operational value.
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
Pharma pricing shifts beyond PBM rebates as Medicare and cash channels reshape launches, WAC cuts and access strategies.
Advertisement
Advertisement